Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04475224
Status:
UNKNOWN
Last Update Posted:
2022-08-26
First Post:
2020-07-12
Brief Title:
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Sponsor:
Kringle Pharma Inc
Organization:
Kringle Pharma Inc
Study Overview
Official Title:
A Non-randomized Multicenter Confirmatory Study by Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is non-randomized multicenter confirmatory study by intrathecal administration of KP-100IT code of HGF Hepatocyte Growth Factor formulation for intrathecal injection in subjects with acute spinal cord injury
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None